Hempyre Holdings Ltd. Launches Global Platform for Branded Hemp-Formulated Consumer Packaged Goods
28.4.2020 13:00:00 EEST | Business Wire | Press release
Hempyre Holdings Ltd. (“Hempyre” or the “Company”) is pleased to announce the launch of a global distribution platform of branded hemp-formulated consumer packaged goods focused on beauty, beverage, and wellness.
Headquartered in London, Hempyre has agreed to acquire CMLM Holdings, Inc., dba QIND, a U.S.-based provider of hemp-formulated wellness and beauty products featuring CBD and CBG. Hempyre has also agreed to acquire select beverage and topical brands in the United Kingdom and China and has actively been hiring local executive talent.
Hempyre’s management team is led by Mr. Shannon Soqui, Chief Executive Officer, and Mr. Jason Roth, Chief Strategy Officer. Mr. Soqui was formerly the Chief Executive Officer of QIND, and Mr. Roth was the Co-Founder, Chairman, and Chief Executive Officer of Mile High Labs until October 2019.
Mr. Soqui has 25 years of experience advising and financing emerging growth companies in disruptive markets, including retail and consumer packaged goods. Mr. Soqui has worked exclusively in the cannabis and hemp industry since 2014, after a successful 25-year career in Silicon Valley as an investment banker with firms such as Credit Suisse and UBS, a securities lawyer with Brobeck, Phleger & Harrison, and a CPA with KPMG.
“As hemp becomes legal in more countries, we see a tremendous opportunity for a branded consumer packaged goods platform focused on beauty, beverages, and wellness in selected markets,” said Mr. Soqui. “With a focus on high quality products that are legally compliant, tested and safe, and developing a broad global distribution platform, both wholesale and online, we believe that we will be well positioned to develop brand recognition globally.”
Mr. Roth has 25 years of experience owning consumer packaged goods and medical device companies that have operated internationally, and is respected for his strategic leadership and disciplined approach to driving revenue.
“The European beverage market has very attractive business and financial dynamics given the recent legalization of hemp-infused beverages in the United Kingdom and other parts of Europe,” said Mr. Roth. “Asia is also a very attractive market for us. Our partnerships with major distribution partners and key opinion leaders will enable us to reach hundreds of millions of consumers very effectively.”
About Hempyre
Hempyre is an emerging global provider of branded hemp-formulated consumer packaged goods focused on Beauty, Beverage, and Wellness. Hempyre’s Beauty product line focuses on consumer hemp-formulated topical solutions to protect and rejuvenate their skin and body. Hempyre’s Beverage product line focuses on consumers who are looking for healthy ways in which to consume hemp-formulated distilled alcoholic and non-alcoholic spirits, sparkling and live sodas, pressed juices, water, and other ready-to-drink offerings. Hempyre’s Wellness product line focuses on consumers looking for hemp-derived CBD and CBG alternatives to treat anxiety, inflammation, insomnia, pain, or to manage and regulate their overall health.
Hempyre’s core strategy focuses on product branding and distribution in Europe, China, the U.S., and the Asia-Pacific region, while outsourcing most aspects of raw material production and finished goods manufacturing. Hempyre currently has 11 brands with more than 150 product SKUs across its three product segments. Hempyre’s hemp-formulated products are non-psychoactive and are made from high quality strains of hemp oil extracts containing either pure CBD or CBG, or combined with a broad or full spectrum of hemp compounds, including other cannabinoids and terpenes.
Hempyre’s primary operating subsidiaries are located in London, England, and Portland, Oregon, with additional staff in Hong Kong, and Auckland, New Zealand. With its licenses and permits, and given the emerging legalization of hemp-formulated products, Hempyre exports selected hemp-formulated CBD and CBG products from the U.S. to selected developed countries globally. Hempyre’s U.S. operations are licensed as a hemp handler by the Oregon Department of Agriculture, and act as a base for distribution throughout the U.S., with shipment enabled by the USPS. For raw material production and finished goods manufacturing, Hempyre’s strategy is to rely on farmers and concentrate processors in the U.S. for raw materials, and GMP-certified co-packers and white-label manufacturers for finished goods assembly or production. Hempyre’s hemp-formulated CBD and CBG products are distributed through its global network of distributors and wholesalers, its own and third-party owned e-commerce websites, Company-leased storefronts, and a variety of brick and mortar mainstream retailers. For more information visit www.hempyre.com.
Strategic Opportunities:
Hempyre is interested in discussing potential acquisitions of branded product and/or distribution companies in the Beauty, Beverage, or Wellness segments that could infuse CBD and CBG into their products.
Please contact jason@hempyre.com for information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200428005331/en/
Contact information
U.S. Media Contact:
Mr. Erik Ritchie
media@hempyre.com
888-743-6797
U.K. Media Contact:
Mr. William Draper
media@hempyre.com
+44 (0) 800 020 9806
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
